Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

895
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
895
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

706
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
706
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

406
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
406
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

305
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
305

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic theoretical and electrochemical evaluation of sulfonamide-based inhibitors for mild steel corrosion in HCl.

RSC advances·2026
Same author

In situ biotransformation of synthetic glutamate to γ-amino butyric acid by an auxotrophic Lactococcus lactis in polysorbate-mediated thermoaerobic process.

Biodegradation·2026
Same author

Chemical Profiling, Pharmacological Activities, and Toxicity Assessment of <i>Juniperus phoenicea</i> sp. <i>turbinata</i> L. Extract: Integrated In Vitro, In Vivo, and In Silico Insights.

Food science & nutrition·2026
Same author

Exploring ethyl methane sulphonate induced, L-cysteine HCl resistant Bacillus subtilis putative mutant and its immobilization for enhanced acetoin synthesis.

Archives of microbiology·2026
Same author

Retraction notice to "Nephroprotective effect of AT-MSCs against cisplatin-induced EMT is improved by azilsartan via attenuating oxidative stress and TGF-β/Smad signaling" [Biomedicine & Pharmacotherapy 158 (2023) 114097].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Neuroprotective Effects of Carnosine Against Corticosterone-Induced Depression and Memory Impairment.

Food science & nutrition·2026

Related Experiment Video

Updated: May 31, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.4K

Dronedarone a comprehensive drug profile.

Ahmed H Bakheit1, Khaled Abdelrazaq2, Hamad M Alkahtani2

  • 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia; Department of Chemistry, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan.

Profiles of Drug Substances, Excipients, and Related Methodology
|January 24, 2025
PubMed
Summary
This summary is machine-generated.

This profile details Dronedarone, an antiarrhythmic drug for irregular heartbeats. It covers nomenclature, physical properties, preparation, analysis, pharmacology, and clinical use.

Keywords:
Analytical methodsAntiarrhythmic medicationAppearanceClinical applicationsDronedaroneFormulaMechanism of actionMethods of preparationNomenclaturePharmacokineticsPharmacologyPhysical characteristicsStability

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.0K

Related Experiment Videos

Last Updated: May 31, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.4K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K
Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

2.0K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Drug Development

Background:

  • Dronedarone is an antiarrhythmic medication.
  • It is used to manage irregular heartbeats.
  • Understanding its properties is crucial for safe and effective use.

Purpose of the Study:

  • To provide a comprehensive drug profile of Dronedarone.
  • To detail its chemical, physical, and analytical characteristics.
  • To explore its clinical applications and pharmacological aspects.

Main Methods:

  • Literature review and data compilation.
  • Analysis of nomenclature, formulae, and physical properties.
  • Examination of preparation, analytical methods, stability, pharmacology, and pharmacokinetics.

Main Results:

  • Detailed information on Dronedarone's IUPAC name, empirical formula, molecular weight, and CAS number.
  • Characterization of physical properties like color, form, melting point, and solubility.
  • Summary of stability, clinical applications, mechanism of action, and pharmacokinetics.

Conclusions:

  • Dronedarone is a well-characterized antiarrhythmic agent.
  • This profile serves as a valuable resource for researchers and clinicians.
  • Comprehensive data supports its therapeutic application in managing cardiac arrhythmias.